CheckMate 77T

Prespecified interim analysis results from CheckMate 77T trial of neoadjuvant nivolumab or placebo plus chemotherapy and adjuvant nivolumab or placebo in stage II to IIIB NSCLC, as presented at ESMO Congress 2023 and reported by Clinical Care Options (CCO)

MD Anderson Research Highlights: ESMO 2023 Special Edition

Gaining an Advantage Over NSCLC: How to Achieve the Greatest

CheckMate-77T Trial Meets Primary EFS End Point in Resectable NSCLC

Sergio Vázquez on X: Another player in the perioperative game

Adding Adjuvant Nivolumab Builds on Standard of Care for

Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and

Ahmed Magdy Rabea on LinkedIn: Thank you IASLC for the amazing

Perioperative Therapy for Resectable Non–Small-Cell Lung Cancer

Cancers, Free Full-Text

Shaheenah Dawood on LinkedIn: On March 4 2022, the FDA approved

Lifescience Dynamics Limited on LinkedIn: #asco23 #asco23 #merck

ESMO: Key insights from Phase III trial CheckMate 77T

Revisiting neoadjuvant therapy in non-small-cell lung cancer - The